General
Preferred name
escitalopram
Synonyms
ESCITALOPRAM OXALATE ()
Seroplex ()
S-(+)-Citalopram ()
(S)-Citalopram ()
Cipralex ()
(S)-(+)Citalopram oxalate ()
Escitalopram (oxalate) ()
(S)-(+)-Citalopram ()
(S)-Citalopram (oxalate) ()
(S)-(+)-Citalopram (oxalate) ()
NSC-758934 ()
LU 26-054-0 ()
Lexapro ()
Escitalopram (as oxalate) ()
LU-26-054-0 ()
LU-26-054-O ()
Citalopram oxalate, (s)- ()
ESITOL ()
ESERTIA ()
LU-26-054 ()
P&D ID
PD009760
CAS
128196-01-0
219861-08-2
Tags
available
probe
drug
Approved by
FDA
First approval
2002
Drug indication
Anxiety disorder
Major depressive disorder
cocaine dependence
Drug Status
approved
Max Phase
4.0
Probe info
Probe type
experimental probe
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ¡«30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression[1][2].
DESCRIPTION
Escitalopram is a selective serotonin-reuptake inhibitor (SSRI) drug. It is the S-enantiomer of .
Marketed formulations may contain escitalopram oxalate (PubChem CID 146571). An X-ray structure of SERT bound by escitalopram ((S)-citalopram) reveals two binding sites for the drug: one central site, and one allosteric site . When (S)-citalopram binds the allosteric site, it prevents unbinding of ligand at the central site, thereby preventing further ligand transport. (GtoPdb)
Marketed formulations may contain escitalopram oxalate (PubChem CID 146571). An X-ray structure of SERT bound by escitalopram ((S)-citalopram) reveals two binding sites for the drug: one central site, and one allosteric site . When (S)-citalopram binds the allosteric site, it prevents unbinding of ligand at the central site, thereby preventing further ligand transport. (GtoPdb)
DESCRIPTION
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ¡«30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression[1][2].
PRICE
44
MOA
Inhibitor
(Chemical Probes.org)
DESCRIPTION
Potent 5-HT and NA reuptake inhibitor (SNRI); also blocks dopamine reuptake
(Tocris Bioactive Compound Library)
DESCRIPTION
Selective serotonin reuptake inhibitor (SSRI)
(Tocriscreen Plus)
DESCRIPTION
Escitalopram is a selective serotonin re-uptake inhibitor used in the treatment of major depressive disorder, generalized anxiety disorder, and other select psychiatric disorders such as obsessive-compulsive disorder.
(Enamine Bioactive Compounds)
DESCRIPTION
Escitalopram Oxalate ((S)-(+)Citalopram oxalate) is a selective serotonin (5-HT) reuptake inhibitor (SSRI) with Ki of 0.89 nM.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Escitalopram (Seroplex) is a furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
31
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Chemical Probes.org
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
EUbOPEN Chemogenomics Library
Guide to Pharmacology
High-quality chemical probes
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
64
Molecular Weight
324.16
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
3.81
TPSA
36.26
Fraction CSP3
0.35
Chiral centers
1.0
Largest ring
6.0
QED
0.84
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Transporters
Target
Endogenous Metabolite
5-HT
Serotonin Transporter
SSRI
Sert (Sodium-dependent)
mAChR
¦Á-adrenergic receptor
DA transporter
H1 receptor
Noradrenaline transporter (Sodium-dependent)
ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4
SLC6A4
α-adrenergic receptor
Pathway
Metabolic Enzyme/Protease
GPCR/G protein
Immunology/Inflammation
Neuroscience
Neuronal Signaling
Primary Target
5-HT Transporters
MOA
5-HT Receptor inhibitor
AChR antagonist
Adrenergic Receptor agonist
Dopamine Receptor antagonist
Histamine Receptor antagonist
Norepinephrine antagonist
Inhibitor
selective serotonin reuptake inhibitor (SSRI)
Indication
depression, generalized anxiety disorder (GAD)
depression
Therapeutic Class
Antidepressants
Target class
Transporter
Target subclass
Serotonin transporter
Recommended Cell Concentration
None
Source data
